Clinical trials: open to volunteers, in Denmark
Coronary Revascularization, Coronary Artery Disease
The CORE Platform Trial
Background: The leading cause of death worldwide is cardiovascular disease, with an estimated 19.8 million deaths per year. Coronary artery disease is a type of cardiovascular disease that can be treated with revascularisation…
- Trial name
- CORE (NCT07892976)
- Testing
- MIDCAB procedure, CABG procedure
- Where
- 3 sites in Belgium, Denmark and 1 more
- Volunteers
- 15,000 people
- Sponsor
- Copenhagen Trial Unit, Center for Clinical Intervention Research
Melanoma, Non Small Cell Lung Cancer
Dabrafenib and/or Trametinib Rollover Study
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
- Trial name
- NCT03340506
- Testing
- dabrafenib, trametinib
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Ischemia, Myocardial, Coronary Artery Disease
Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated With Percutaneous Coronary Intervention
The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer…
- Conditions
- Ischemia, Myocardial, Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)
- Trial name
- SORT OUT XII (NCT06692140)
- Testing
- Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s), PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
- Where
- 3 sites in Denmark
- Volunteers
- 3,150 people
- Sponsor
- Odense University Hospital
Maxillary Retrognathism, Children
Treatment of Mandibular Overjet in Children With Maxillary Retrognathism
The project involves a 10-year prospective longitudinal cohort multicentre study where orthodontic treatment and treatment effect is followed in children with Cl III due to maxillary retrognathia who undergo standardized…
- Conditions
- Maxillary Retrognathism, Children, Treatment, Class III Malocclusion
- Trial name
- NCT07706400
- Testing
- Interceptive treatment
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Malmö University
Cancer, Type 2 Diabetes
QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy
The goal of this observational study is to see how type 2 diabetes affects quality of life in cancer patients receiving immunotherapy.
- Trial name
- QoLIDia (NCT07466212)
- Where
- 4 sites in Denmark
- Volunteers
- 920 people
- Sponsor
- Odense University Hospital
Egg Allergy, Egg Hypersensitivity
Oral Immunotherapy for Children With Egg Allergy
This clinical trial aims to investigate if oral immunotherapy can help children with egg allergy tolerate eggs. Children aged 6-18 months can take part in the trial.
- Conditions
- Egg Allergy, Egg Hypersensitivity, Food Allergy in Children, Food Allergies
- Trial name
- NCT07888439
- Testing
- Oral immunotherapy with egg
- Where
- 5 sites in Denmark
- Volunteers
- 76 people
- Sponsor
- Laura Ozer Kettner
Spasticity, Muscle
Effect of Treatment Dairy for Spasticity
1. Assessing whether the treatment diary can help optimize the overall treatment of patients. 2. To assess whether the patient finds the treatment diary useful and worth spending time on.
- Trial name
- NCT03384927
- Where
- Denmark
- Volunteers
- 96 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Mesothelioma, Pancreatic Cancer
A 2-part Phase 1/2 Open-label Trial on ODM-212
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
- Conditions
- Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
- Trial name
- TEADCO (NCT07563738)
- Testing
- ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel
- Where
- 23 sites in United States, Denmark and 5 more
- Volunteers
- 229 people
- Sponsor
- Orion Corporation, Orion Pharma
ARDS, Human
Pulmonary Immune Cell-microbiome Interactions in ARDS
The overall aim is to compare the composition and spatial heterogeneity of the following in critically ill intensive care unit (ICU) patients: i) immune cell populations and their activation patterns, ii) the surrounding…
- Trial name
- ILLUMINA-1 (NCT05795257)
- Testing
- Bronchoalveolar lavage
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Hvidovre University Hospital
Prostatic Neoplasms, Castration-Resistant
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01).
- Trial name
- NCT06353386
- Testing
- Opevesostat, Olaparib, Docetaxel
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one…
- Trial name
- Prevent-HF (NCT06677060)
- Testing
- Baxdrostat and dapagliflozin
- Where
- 977 sites in United States, Argentina and 33 more
- Volunteers
- 11,300 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214…
- Trial name
- NCT06004245
- Testing
- VVD-133214, Pembrolizumab, Bevacizumab
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 280 people
- Sponsor
- Vividion Therapeutics, Inc.
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
DLBCL, Diffuse Large B-Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the…
- Trial name
- NCT05139017
- Testing
- Zilovertamab vedotin, Rituximab, Gemcitabine
- Where
- 135 sites in United States, Argentina and 24 more
- Volunteers
- 290 people
- Sponsor
- Merck Sharp & Dohme LLC
Colon Cancer, Frailty
Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)
The purpose of the study is to investigate whether an extended program (ERAS 3.0) initiated hospital discharge, can improve recovery in elderly, frail patients who have undergone surgery for colon cancer.
- Trial name
- NCT06802991
- Testing
- ERAS 3.0 (Enhanced Recovery After Surgery)
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital at Herlev
Advanced Solid Tumors
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to investigate the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
- Trial name
- NCT06697197
- Testing
- BMS-986482, Pumitamig
- Where
- 21 sites in United States, Belgium and 7 more
- Volunteers
- 286 people
- Sponsor
- Bristol-Myers Squibb
Malignant Neoplasm
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Researchers are looking for new ways to treat children with relapsed or refractory solid tumors: Relapsed means the cancer came back after treatment Refractory means the cancer did not respond (get smaller or go away) to…
- Trial name
- NCT07630974
- Testing
- Ifinatamab Deruxtecan
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 134 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
The BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized, open-label, controlled phase-3 trial evaluating efficacy of ONC201 in…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
- Trial name
- BIOMEDE 2 (NCT05476939)
- Testing
- Everolimus, ONC201, Radiotherapy
- Where
- 56 sites in Belgium, Denmark and 6 more
- Volunteers
- 433 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Transcatheter Aortic Valve Implantation, Dental
Impact of Preoperative Dental Screening in Reducing Infective Endocarditis Risk in Transcatheter Aortic Valve Implantation Patients
In Odense University Hospital preoperative dental screening (PDS) protocol for patients treated with Transcatheter Aortic Valve Implantation (TAVI) was changed from mandatory to targeted PDS to between June 2023 to october 2023.
- Conditions
- Transcatheter Aortic Valve Implantation, Dental, Endocarditis
- Trial name
- DENTAVI (NCT06330766)
- Testing
- No preoperative dental screening
- Where
- Denmark
- Volunteers
- 1,000 people
- Sponsor
- Odense University Hospital
Carcinoma, Renal Cell
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy.
- Trial name
- NCT07489495
- Testing
- Belzutifan, Zanzalintinib
- Where
- 103 sites in United States, Argentina and 17 more
- Volunteers
- 758 people
- Sponsor
- Merck Sharp & Dohme LLC